Ipilimumab
CAS No. 477202-00-9
Ipilimumab ( —— )
产品货号. M22137 CAS No. 477202-00-9
Ipilimumab anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
规格 | 价格/人民币 | 库存 | 数量 |
5MG | ¥8586 | 有现货 |
|
10MG | ¥11583 | 有现货 |
|
25MG | ¥17172 | 有现货 |
|
50MG | ¥23166 | 有现货 |
|
100MG | ¥31185 | 有现货 |
|
200MG | 获取报价 | 有现货 |
|
500MG | 获取报价 | 有现货 |
|
1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Ipilimumab
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述Ipilimumab anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor.
-
产品描述Ipilimumab anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor.
-
同义词——
-
通路Others
-
靶点Other Targets
-
受体Other Targets
-
研究领域——
-
适应症——
化学信息
-
CAS Number477202-00-9
-
分子量148 kDa
-
分子式——
-
纯度>98% (HPLC)
-
溶解度——
-
SMILES——
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Hu-Lieskovan S, et al. Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges. J Clin Oncol. 2014 Jul 20;32(21):2248-54.
产品手册
关联产品
-
S961
S961 is an high-affinity and selective insulin receptor (IR) antagonist with IC50s of 0.048, 0.027, and 630 nM for HIR-A, HIR-B, and human insulin-like growth factor I receptor (HIGF-IR) in SPA-assay, respectively.
-
Phloracetophenone 4-...
Phloracetophenone 4'-O-glucoside is a natural product for research related to life sciences.
-
Deferoxamine mesylat...
An iron chelator that binds iron and aluminium; increases HIF-1α transactivation in diabetes by preventing iron-catalyzed reactive oxygen stress.